Cardioversion
8
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
MAX - SHOCK Clinical Trial
Cardiovascular Performance and Exercise Response in Patients With Persistent or Permanent Atrial Fibrillation and Heart Failure Pre and Post Cardioversion or Pace and Ablate
Heart Watch Study: a Pragmatic Randomized Controlled Trial
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Myocardial Injury Following Elective Direct Current Cardioversion for Atrial Arrhythmias
Renal Function Post Cardioversion for Atrial Fibrillation
Left Atrial Thrombus on Transesophageal Echocardiography
Optimization of Initial Energy for Cardioversion of Atrial Fibrillation With Biphasic Shocks